CALT: תחזית צמיחת רווחים לשנה הבאה Calliditas

The development of unique treatments for rare kidney pathologies ensures stable demand and long-term returns for Calliditas Therapeutics (CALT). The high intellectual potential of Swedish scientists guarantees innovative progress. However, integration with Asahi Kasei and pricing controls in the US are weighing on margins. EPS growth prospects for next year reflect current market expectations, where 2490.80 represents the current level of the metric.

This indicator measures the expected earnings per share (EPS) dynamics for the next period, allowing investors to assess the potential for business expansion and the risk of capital stagnation. By analyzing current expectations for the EPS n+1 growth rate, one can confirm the resilience of Calliditas Therapeutics (CALT), whose innovative medical developments create a demand cycle independent of macroeconomic factors, providing the asset with defensive qualities.